Drug Trial Radar · NCT06023186
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
Last checked: Nov 20, 2026Latest source record: Nov 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Nov 3, 2023
Primary completion
Aug 31, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Michael AyersAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bristol-Myers Squibb
- First posted
- Sep 5, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this observational study is to measure the effect of mavacamten treatment on blood flow in the heart muscle (myocardium) in patients with obstructive hypertrophic cardiomyopathy. The main question it aims to answer is: • Does mavacamten treatment improve blood flow in the heart muscle? Participants will take mavacamten at the direction of their treating physician. Participants will complete 2 myocardial Positron Emission Tomography and Computed Tomography (PET-CT) scans. The first scan will be completed before participants start taking mavacamten. The scan will be repeated after 12 months of mavacamten treatment.
Conditions
- Obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamtenDrug
Study participants will receive mavacamten under the standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in myocardial perfusion reserve after 12 months of mavacamten treatment.Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Virginia
Charlottesville, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.